Download Comparison of Methimazole and Propylthiouracil in Patients with

0021-972X/07/$15.00/0
Printed in U.S.A.
The Journal of Clinical Endocrinology & Metabolism 92(6):2157–2162
Copyright © 2007 by The Endocrine Society
doi: 10.1210/jc.2006-2135
Comparison of Methimazole and Propylthiouracil
in Patients with Hyperthyroidism Caused by
Graves’ Disease
Hirotoshi Nakamura, Jaeduk Yoshimura Noh, Koichi Itoh, Shuji Fukata, Akira Miyauchi,
Noboru Hamada, and Working Group of the Japan Thyroid Association for the Guideline of the
Treatment of Graves’ Disease*
Department of Internal Medicine II (H.N.), Hamamatsu University School of Medicine, Handayama 1-20-1, Hamamatsu,
Shizuoka 4313129, Japan; Ito Hospital (J.Y.N., K.I.), Jingumae 4-3-6, Shibuya-ku, Tokyo 1508308, Japan; Kuma Hospital
(S.F., A.M.), Shimoyamatedori 8-2-35, Chuo-ku, Kobe 6500011, Japan; and Sumire Hospital (N.H.), Furuichi 1-20-85, Jotoku, Osaka 536-0001, Japan
Context: Although methimazole (MMI) and propylthiouracil (PTU)
have long been used to treat hyperthyroidism caused by Graves’
disease (GD), there is still no clear conclusion about the choice of drug
or appropriate initial doses.
Objective: The aim of the study was to compare the MMI 30 mg/d
treatment with the PTU 300 mg/d and MMI 15 mg/d treatment in
terms of efficacy and adverse reactions.
Design, Setting, and Participants: Patients newly diagnosed with
GD were randomly assigned to one of the three treatment regimens
in a prospective study at four Japanese hospitals.
Main Outcome Measures: Percentages of patients with normal
serum free T4 (FT4) or free T3 (FT3) and frequency of adverse effects
were measured at 4, 8, and 12 wk.
D
ESPITE METHIMAZOLE (MMI) and propylthiouracil
(PTU) having been used for more than half a century to
treat hyperthyroidism caused by Graves’ disease (GD), controversy still exists in antithyroid drug (ATD) therapy. For example, according to a survey reported in 1991, MMI was selected
as the drug for initial treatment in Japan and Europe, whereas
PTU was preferred in the United States (1). Which is more
suitable, MMI or PTU, in terms of drug efficacy or adverse
effects? In Japan, treatment with MMI 30 mg daily has been “a
standard regimen” for GD for a long time, but some reports
have insisted that a smaller dosage such as 15 mg daily of MMI
is as effective as the standard of 30 mg (2– 4). How much should
the initial ATD dosage be, a moderate dosage such as 30 mg
daily of MMI or a smaller dosage of 15 mg?
First Published Online March 27, 2007
* See Acknowledgments for members of the Working Group of the
Japan Thyroid Association for the Guideline of the Treatment of Graves’
Disease.
Abbreviations: ALT, Alanine aminotransferase; AST, aspirate aminotransferase; ATD, antithyroid drug; GD, Graves’ disease; MMI, methimazole; PTU, propylthiouracil; RCT, randomized controlled trial; TH,
thyroid hormone; TRAb, thyroid stimulating hormone receptor
antibody.
JCEM is published monthly by The Endocrine Society (http://www.
endo-society.org), the foremost professional society serving the endocrine community.
Results: MMI 30 mg/d normalized FT4 in more patients than PTU
300 mg/d and MMI 15 mg/d for the whole group (240 patients) at 12
wk (96.5 vs. 78.3%; P ⫽ 0.001; and 86.2%, P ⫽ 0.023, respectively).
When patients were divided into two groups by initial FT4, in the
group of the patients with severe hyperthyroidism (FT4, 7 ng/dl or
more, 64 patients) MMI 30 mg/d normalized FT4 more effectively than
PTU 300 mg/d at 8 and 12 wk and MMI 15 mg/d at 8 wk, respectively
(P ⬍ 0.05). No remarkable difference between the treatments was
observed in patients with initial FT4 less than 7 ng/dl. Adverse effects,
especially mild hepatotoxicity, were higher with PTU and significantly lower with MMI 15 mg/d compared with MMI 30 mg/d.
Conclusions: MMI 15 mg/d is suitable for mild and moderate GD,
whereas MMI 30 mg/d is advisable for severe cases. PTU is not
recommended for initial use. (J Clin Endocrinol Metab 92:
2157–2162, 2007)
The Japan Thyroid Association has been formulating a
guideline for the treatment of hyperthyroidism caused by
GD, but the data collected on ATD therapy over time were
indeterminate on drug selection or suitable starting dosage. Therefore, we undertook this prospective randomized
clinical study on initial treatments for thyrotoxic GD to
decide the most suitable regimen by comparing the standard treatment of MMI 30 mg/d with PTU 300 mg/d and
MMI 15 mg/d in terms of the short-term efficacy and
adverse effects.
Patients and Methods
Patients
Only patients with untreated hyperthyroidism due to GD were recruited. GD was diagnosed according to Japan Thyroid Association’s
diagnosis guidelines (http://thyroid.umin.ac.jp/en/frame.html), defined by clinical findings and the determination of serum free T4 (FT4),
free T3 (FT3), TSH, TSH receptor antibody (TRAb), and 123I- or 99mTcuptake. The following conditions excluded patients from the study: age
younger than 16 yr old; pregnancy; relapsed patients after subtotal
thyroidectomy or radioiodine therapy; previous treatment with ATD;
severe complications, such as heart failure; and patients on glucocorticoid steroids or drugs that may influence thyroid functions.
Study design
This study was conducted as an open prospective randomized trial,
with an observation period of 12 wk. Four hospitals in Japan, Ito Hospital
2157
2158
J Clin Endocrinol Metab, June 2007, 92(6):2157–2162
Nakamura et al. • ATD Therapy for GD
in Tokyo, Kuma Hospital in Kobe, Sumire Hospital in Osaka, and
Hamamatsu University Hospital in Hamamatsu, participated in the
study. The Ethical Committee of Hamamatsu University School of Medicine and each hospital involved in the study approved the protocol. All
eligible patients with untreated GD seen by the four participating hospitals from October 2003 to July 2004 were registered for the trial after
obtaining informed consent. To compare the efficiency between MMI 30
mg/d and PTU 300 mg/d or MMI 15 mg/d, patients were distributed
at random to the group with MMI 30 mg/d in two divided doses, PTU
300 mg/d in three divided doses or MMI 15 mg/d in a single dose. The
necessary sample size was estimated by statistical calculation. For example, when type I error is 0.05, power is 0.8, and efficacy is 60% vs. 40%,
82 patients in each group are required. The method of assigning patients
to groups was by their admission order at the outpatient clinic in Sumire
Hospital and Hamamatsu University Hospital, and by the day of the
week when patients first visited the outpatient clinic in Ito Hospital and
Kuma Hospital.
A total of 396 patients with untreated GD were initially recruited for
the study, with 93 patients excluded from the final analysis of the ATD
treatment due to the reasons in Table 1. The percentage of withdrawal
was less in the MMI 15-mg group than for other groups due to the
significantly less occurrence of early adverse effects. Finally, 303 patients
(134 patients at Ito Hospital, 92 at Kuma Hospital, 62 at Hamamatsu
University Hospital and 15 at Sumire Hospital) were evaluated. For the
adverse event analysis, 371 patients (excluding 25 dropout patients)
were examined.
Patients were scheduled to visit the hospitals at 2, 4, 8, and 12 wk after
initiation of their treatment. Adverse effects of the drugs were looked for
systematically by careful health interview and clinical examinations.
Aspirate aminotransferase (AST), alanine aminotransferase (ALT), ␥
glutamyl transpeptidase, and hematological values were measured for
evaluation every visit to the outpatient clinic. Serum FT4 and FT3 with
or without TSH were assayed at 4, 8, and 12 wk. When serum FT4 and
FT3 were both within normal ranges (FT4, 0.8 –1.6 ng/dl; FT3, 3.1– 4.9
pg/ml), the dosages of ATD were lessened as follows: MMI from 30 to
15 mg; from 15 to 10 mg; and PTU from 300 to 150 mg. After that, patients
were given suitable doses of ATD to maintain normal thyroid hormone
(TH) concentrations. When necessary, ␤-blocker was given concomitantly. The initial dose of ATD was continued without increasing for 12
wk, even if TH did not fall into the normal range. Each of the four
hospitals obtained the values for serum FT4 and FT3 within 60 min after
taking blood samples at outpatient clinics, and doctors could decide the
dose of ATD after checking hormone values.
The number of patients finally analyzed for ATD effectiveness was
98 in the MMI 30-mg, 81 in the PTU 300-mg, and 124 in the MMI 15-mg
groups, respectively. The ratio of sex, values for age, and initial TRAb
before treatment did not differ between groups (Table 1). Before ATD
treatment, all patients had elevated FT4 levels more than 2 ng/dl.
Methods
Serum FT4, FT3, and TSH were measured with a Roche ECLusys kit
(Roche, Basel, Switzerland) in Ito Hospital, Sumire Hospital, and
Hamamatsu University Hospital, or Architect kits (Abbott Japan Co.,
Ltd, Osaka 540-0001 Japan) in Kuma Hospital. Although values for the
hormones obtained by these two assay kits differed slightly, the data
were combined for the analyses because the difference was small (data
not shown). The normal values and measurable ranges are as follows:
FT4 0.8 –1.6 ng/dl (measurable range up to 7 ng/dl), FT3 3.1– 4.9 pg/ml
(measurable range up to 30 pg/ml). TRAb (normal range 0 –10%) was
assayed with TRAb-CT (Cosmic Corporation, Tokyo, Japan).
Statistical analysis
Data were analyzed statistically using the ␹2 test for independence
and comparison of frequencies. When expected values less than 5 are
included in the table of the data, Fisher’s exact probability test was used
instead of the ␹2 test. For comparison of age and TRAb values among
the three groups, ANOVA was used. Calculations were performed using
StatView, version 5.0 (SAS Institute Inc., Cary, NC). Statistical significance was defined as P ⬍ 0.05.
Results
Comparisons of the efficiency of the MMI 30 mg/d
treatment with that of the PTU 300 mg/d and MMI 15
mg/d treatment
At 4 wk after initial treatment, serum FT4 levels went
down less than 1.7 ng/dl in 52.7%, 38.4%, and 36.7% of the
patients treated with MMI 30 mg/d, PTU 300 mg/d, and
MMI 15 mg/d, respectively. MMI 15 mg/d was significantly
less effective than MMI 30 mg/d (P ⫽ 0.023). At 8 wk, their
ratios were 81.3%, 68.5%, and 70.0%, respectively, and the
statistical difference between MMI 30 mg/d with PTU 300
mg/d and MMI 15 mg/d was marginal. At 12 wk, the efficacy was significantly different between them because 96.5%
of the patients on MMI 30 mg reached normal FT4, while
78.3% on PTU 300 mg (P ⬍ 0.001) and 86.2% on MMI 15 mg
(P ⫽ 0.023) (Fig. 1).
Because the severity of hyperthyroidism varied among the
patients, we divided the patients into two groups according
to their pretreatment serum FT4 values; group A included
patients with initial FT4 less than 7 ng/dl and group B with
7 ng/dl or more. There was no difference in the pretreatment
FT4 and FT3 values in group A (data not shown), and almost
all patients in group B had FT4 above the measurable range.
In group A, no difference was found between the treatments
at 4 and 8 wk, but at 12 wk, MMI 30 mg/d achieved normal
FT4 in every patient, while PTU 300 mg/d and MMI 15 mg/d
induced normal FT4 in 87.5% and 92%, respectively, with a
statistically significant difference (Fig. 2, upper). In group B,
MMI 30 mg/d is clearly more effective than PTU 300 mg/d
and MMI 15 mg/d in normalizing FT4. At 4 wk after beginning treatment, 38.5% of the patients achieved normal FT4
with MMI 30 mg/d, but only 13.0% with PTU 300 mg/d and
14.3% with MMI 15 mg/d, with both about 35– 40% efficiency
of MMI 30 mg/d in normalizing FT4. The same tendency was
observed at 8 and 12 wk also (Fig. 2, lower).
TABLE 1. Patient groupings and data
MMI 30 mg/d
PTU 300 mg/d
MMI 15 mg/d
Total
No. of patients
randomized
No. of patients
excluded (%)
No. of side
effects (%)
No. of patients
not visiting
regularly (%)
No. of
dropouts
(%)
No. of
patients
analyzed
Male to
female
ratio
Mean age
⫾ SD (yr)
Initial TRAb
values
135
114
147
396
37 (27.4)
33 (28.9)
23 (15.6)
93 (21.8)
24 (17.8)
20 (17.5)
8 (5.4)
52 (13.1)
8
3
5
16 (4.0)
5 (3.7)
10 (8.8)
10 (6.8)
25 (5.9)
98
81
124
303
25/73
11/70
26/98
39.4 ⫾ 13.5
40.2 ⫾ 12.9
41.0 ⫾ 13.1
67.8 ⫾ 35.2
56.3 ⫾ 23.8
61.0 ⫾ 24.9
A total of 396 patients with untreated GD were initially recruited for the study, with 93 patients excluded from the final evaluation for
short-term efficacy of the ATD treatments due to side effects within 4 wk, not visiting a hospital regularly, or dropout. Finally, 303 patients
(134 patients at Ito Hospital, 92 at Kuma Hospital, 62 at Hamamatsu University Hospital, and 15 at Sumire Hospital) were analyzed. For the
adverse event analysis, 371 patients excluding 25 dropout patients were examined.
Nakamura et al. • ATD Therapy for GD
J Clin Endocrinol Metab, June 2007, 92(6):2157–2162
0 .0 0 3
(% )
#
0 .1 0 5
100
Ratio of the patients with normal FT 4
2159
0 .0 0 1*
80
0 .0 5 2
0 .0 5 7
0 .0 2 3
*
0 .0 6 0
60
0 .0 6 6
40
20
0
4 8/ 9 1
0 .0 2 3 *
74 / 91
5 0 /7 3
82/ 8 5
5 4 /6 9
28 / 7 3
4W
12 W
8W
MMI 30mg/day
PTU 300mg/day
MMI 15mg/day
FIG. 1. Comparison of the efficiency of treatment with MMI 30 mg/d and PTU 300 mg/d or MMI 15 mg/d in whole patients with GD in terms
of normalizing serum FT4 levels [⬍1.7 ng/dl (21.9 pmol/liter)]. The numbers in the columns show patients with normal FT4/total patients. The
numbers above the columns are P values of ␹2 analyses between MMI 30 mg/d and PTU 300 mg/d or MMI 15 mg/d. #, Significantly different
among three treatment groups. *, Statistically significant between MMI 30 mg/d and PTU 300 mg/d or MMI 15 mg/d. W, Weeks.
When the efficiency of these ATD regimens was analyzed
in terms of achieving normal FT3 levels (⬍5 pg/ml), a similar
tendency was found, although the difference was less evident (Table 2). For whole patients, MMI 30 mg/d induced
normal FT3 more efficiently than PTU 300 mg/d at 8 wk
(75.6% vs. 57.4%, respectively; P ⫽ 0.021) and 12 wk (90.0%
vs. 62.9%, respectively; P ⬍ 0.001). When the patients in
groups A and B were analyzed, there was no difference
between the treatments at 4 and 8 wk, but at 12 wk, MMI 30
mg/d was more effective than PTU 300 mg/d and MMI 15
mg/d. The efficiency to achieve normal FT3 level was almost
half with PTU 300 mg/d compared with MMI 30 mg/d (66.7
vs. 35.0%, respectively; P ⫽ 0.043) in group B. No relation was
found between the efficacy of ATD to normalize TH and age,
sex, initial TRAb values, or goiter size (data not shown).
Comparison of adverse events between MMI 30 mg/d and
PTU 300 mg/d or MMI 15 mg/d
Table 3 summarizes the incidence of adverse effects in the
ATD regimen groups. The incidence was surprisingly high
in the PTU group, in which more than half the patients (54
of 104) had some adverse effects. PTU was stopped or
changed to MMI for 39 patients. In the MMI 30-mg group,
adverse effects occurred in 39 of 130 patients (30%), and the
drug was stopped or changed for 28 patients. The difference
was statistically significant between the PTU group and the
MMI 30-mg group. We found a very high incidence of elevation of transaminase values with PTU. The percentage of
patients who showed AST and ALT higher than double the
upper range of the normal standard was 26.9% on PTU 300
mg/d, compared with only 6.6% on MMI 30 mg/d (P ⬍
0.001). Skin eruption or urticaria similarly occurred in about
22% in either group, but leukocytopenia (less than 1000/␮l)
was observed in five patients in the PTU group only. One
patient treated with MMI 30 mg/d had arthralgia, and the
drug was discontinued. Fortunately, no patient experienced
serious side effects, such as agranulocytosis.
On the contrary, MMI 15 mg/d caused significantly fewer
adverse events than MMI 30 mg/d. The total incidence in the
MMI 15 mg group was about half that of the MMI 30-mg
group. Although the frequency of mild hepatotoxicity was
similar, skin eruption/urticaria induced by MMI 15 mg was
only about one third that of MMI 30 mg.
Discussion
There have been only limited studies that compared the
effectiveness of MMI and PTU to treat hyperthyroidism
caused by GD. Okamura et al. (5) reported that MMI 30 mg/d
normalized more rapidly TH than PTU 300 mg/d. The mean
time required to normalize TH was 6.7 ⫾ 4.6 wk by MMI and
16.8 ⫾ 13.7 wk by PTU (P ⬍ 0.05). However, their study was
retrospective, and it was unclear whether the patients in each
group were truly equivalent (5). In fact, only 17 patients were
treated with PTU, one fourth that of MMI. There were four
prospective randomized controlled trials (RCTs) to compare
MMI and PTU (6 –9), and the results of these studies indicated the tendency that MMI is somewhat more effective.
However, the conclusion should be cautious because of the
small number of patients in each group (6, 7, 9). In addition,
in one study, both ATDs were given in a single daily usage
(8). Because the half-life of PTU is much shorter than that of
MMI and a single daily dose regimen is known to be less
effective than a divided dose regimen for PTU administra-
2160
J Clin Endocrinol Metab, June 2007, 92(6):2157–2162
Nakamura et al. • ATD Therapy for GD
Ratio of the patients with normal FT4
Group A: FT4 <7ng/dl
0.025
#
(%)
100
*
0.042
*
0.006
80
60
40
38
65
20
25
50
36
57
42
77
62
42
80
81
65
49
93
62
48
87
0
4W
Ratio of the patients with normal FT4
Group
12W
8W
: FT4 >7ng/dl
=
(%)
0.075
100
0.009
#
80
*
0.091
0.042
60
0.047
#
*
40
0.024
*
0.004
17
20
10
26
26
0.063
0.057
20
23
8/24
7/27
12
14
21
22
3/23 4/28
0
4w
MMI
30mg/day
8w
PTU
300mg/day
12W
MMI
15mg/day
FIG. 2. Comparison of the efficiency of treatment with MMI 30 mg/d and PTU 300 mg/d or MMI 15 mg/d in patients with GD in terms of
normalizing serum FT4 levels [⬍1.7 ng/dl (21.9 pmol/liter)]. The patients were divided into two groups according to their pretreatment serum
FT4 values: group A with initial FT4 less than 7 ng/dl (90 pmol/l) (upper) and group B with 7 ng/dl or more (lower). The numbers in the columns
show patients with normal FT4/total patients. The numbers above the columns are P values of ␹2 analyses between MMI 30 mg/d and PTU 300
mg/d or MMI 15 mg/d. #, Significantly different among three treatment groups. *, Statistically significant between MMI 30 mg/d and PTU 300
mg/d or MMI 15 mg/d. W, Weeks.
tion (10), comparison between MMI and PTU in a single daily
usage may be unsuitable.
As for the initial dosage of ATD, Benker et al. (11) reported
that 42.2% of patients became euthyroid within 3 wk on MMI
10 mg/d and 64.8% on 40 mg/d after 3 wk in the European
Multicenter Trial Study. At 6 wk, 77.5% and 92.6% of patients
became euthyroidism on 10 mg and 40 mg MMI, respectively. In an RCT comparing the effects of 20, 30, 40 mg/d
MMI, and 200, 300, 400 mg/d PTU, Kallner et al. (7) showed
that almost all patients had a normal FT4 level within 12 wk
except those who received 20 mg MMI or 200 mg PTU. They
concluded that these small doses of ATD were unsuitable
due to an unacceptably high incidence of failure to attain
euthyroidism within 12 wk. In contrast, Shiroozu et al. (2)
reported similar effectiveness between MMI 15 mg/d and 30
mg/d, showing that the percentage of patients who became
euthyroid and the mean times to achieve it were similar
among the groups. Following this report, Mashio et al. (3)
performed a similar study and confirmed the conclusion of
Shiroozu et al. (2). The results of both studies are clear, but
Nakamura et al. • ATD Therapy for GD
J Clin Endocrinol Metab, June 2007, 92(6):2157–2162
2161
TABLE 2. Comparison of the efficiency of treatment with MMI 30 mg/d and PTU 300 mg/d or MMI 15 mg/d in patients with GD in terms
of normalizing serum FT3
At 4 wk
MMI 30 mg
PTU 300 mg
P value (␹2)
MMI 15 mg
P value (␹2)
P value (␹2) among three groups
At 8 wk
MMI 30 mg
PTU 300 mg
P value (␹2)
MMI 15 mg
P value (␹2)
P value (␹2) among three groups
At 12 wk
MMI 30 mg
PTU 300 mg
P value (␹2)
MMI 15 mg
P value (␹2)
P value (␹2) among three groups
No./total no. of
patients (%)
No./total no. of
patients in group A (%)
No./total no. of
patients in group B (%)
39/80 (48.8)
24/62 (38.7)
0.232
32/92 (34.8)
0.064
0.166
34/57 (59.6)
24/46 (52.2)
0.447
30/71 (42.3)
0.0498a
0.143
5/23 (21.7)
0/16 (0.0)
0.066
2/21 (9.5)
0.416
0.107
62/82 (75.6)
35/61 (57.4)
0.021a
62/96 (64.5)
0.111
0.064
52/61 (85.2)
30/42 (71.4)
0.090
54/72 (75.0)
0.139
0.196
10/21 (47.6)
5/19 (26.3)
0.204
8/24 (33.3)
0.329
0.354
72/80 (90.0)
39/62 (62.9)
⬍0.001
78/98 (79.6)
0.058
⬍0.001b
58/59 (98.3)
32/42 (76.2)
⬍0.001a
66/77 (85.7)
0.013a
0.003b
14/21 (66.7)
7/20 (35.0)
0.043a
12/21 (57.1)
0.525
0.115
FT3 was considered normalized when it became less than 5 pg/ml (7.68 pmol/liter). Group A patients are those with pretreatment serum
FT4 less than 7 ng/dl (90 pmol/liter) and group B with 7 ng/dl or more.
a
Statistically significant compared with MMI 30-mg group.
b
Statistically significant among the three groups.
there were some limitations. In the RCT by Shiroozu et al. (2),
a significant number of patients were considered to be mild
because 20 –35% of the patients had TRAb values less than
15%. In addition, the dropout ratio was as high as 20%, and
a retrospective control group was included. In the study by
Mashio et al. (3, 4), no information was given about the ratio
of dropout patients. Both studies did not pay any attention
to the baseline severity of the disease before treatment. Analysis based on the baseline severity of hyperthyroidism is
important because it is quite conceivable that a small amount
of ATD may be suitable for mild GD but unsuitable for very
severe hyperthyroid patients. There has been only one study
reporting such an analysis (12), which observed that 20 mg/d
carbimazole, a precursor of MMI, was too low for severe
Graves’ patients (initial T4 ⬎ 20 ␮g/dl) but adequate for less
severely hyperthyroid patients. The data are interesting and
suggestive, but the number of patients in each group was
very small (just seven to nine subjects). Our RCT showed that
the MMI 30 mg/d treatment is clearly superior in the effectiveness to achieve normal TH than PTU 300 mg/d and MMI
15 mg/d, especially for patients with severe
hyperthyroidism.
Regarding adverse effects, minor ones occurred in as high
as 52% of patients treated with PTU 300 mg/d, while 30%
and 13.9% with MMI 30 mg/d and MMI 15 mg/d, respectively, in our study. The frequency of minor side effects was
reported not to differ between MMI and PTU (13), but this
is the first RCT that demonstrated the significantly higher
frequency of adverse effects in PTU than MMI. Notably PTU
induced mild liver damages four times higher than MMI 30
mg/d. Liaw et al. (14) reported that although PTU commonly
induces subclinical and asymptomatic liver injury, liver
damage is usually transient, and PTU may be continued with
caution. However, we stopped the initial medication when
AST or ALT elevated more than double the normal level
because of the risk of PTU-induced severe hepatotoxicity.
Williams et al. (15) collected two of their own and 28 cases in
the literature of PTU-induced severe hepatic toxicity and
reported that seven patients died. MMI 15 mg/d is evidently
advantageous over MMI 30 mg/d, with a total incidence less
TABLE 3. Comparison of the incidence of side effects between the MMI 30 mg/d regimen and the PTU 300 mg/d or MMI 15 mg/d
regimen
MMI 30 mg
PTU 300 mg
P value (␹2)
MMI 15 mg
P value (␹2)
a
n
No. of total
incidences (%)
No. with changed
medication (%)
No. with
hepatotoxicity (%)a
No. with skin
eruption/urticaria (%)
No. with
leukocytopenia (%)b
No. with
other (%)c
130
104
0.001d
137
0.001d
39 (30.0)
54 (51.9)
0.007d
19 (13.9)
0.001d
28 (21.5)
39 (37.5)
⬍0.001d
10 (7.3)
0.908
9 (6.6)
28 (26.9)
0.972
9 (6.6)
⬍0.001d
29 (22.3)
23 (22.1)
0.016d
9 (6.6)
⬎0.999
0 (0)
5 (4.8)
1 (0.7)
0 (0)
1 (0.7)
0 (0)
Elevation of AST and ALT more than double the upper range of the normal standard.
Less than 1000/␮l.
c
Arthralgia.
d
Statistically significant.
b
2162
J Clin Endocrinol Metab, June 2007, 92(6):2157–2162
Nakamura et al. • ATD Therapy for GD
than half and the frequency of skin eruption one third of MMI
30 mg/d. This result was compatible with that of Shiroozu
et al. (2) and Benker (11) et al.
In conclusion, we recommend MMI 15 mg/d for patients
with mild and moderate GD. MMI of this dosage can induce
euthyroidism as effectively as MMI 30 mg/d, and the frequency of adverse reaction is significantly lower. For severe
Graves’ patients, MMI 30 mg/d may be advisable to induce
euthyroidism within 3 months. PTU is not recommended as
an initial ATD because of its high frequency of adverse reactions and rather poor efficacy to decrease TH levels.
7.
Acknowledgments
8.
The members of the Working Group of the Japan Thyroid Association
for the Guideline of the Treatment of Graves’ Disease are Yoshifumi Abe,
Nobuyuki Amino, Koichi Ito, Makoto Iitaka, Ken Okamura, Yasunori
Ozawa, Keiichi Kamijo, Jun Sasaki, Yoshimasa Shishiba, Yuji Tanaka,
Junichi Tajiri, Toshio Tsushima, Hirotoshi Nakamura (chairman),
Noboru Hamada, You Hidaka, Shuji Fukata, Tomoaki Mitsuhashi, Akira
Niyauchi, Naoko Momotani, and Jaeduk Yoshimura Noh.
Received September 29, 2006. Accepted March 9, 2007.
Address all correspondence and requests for reprints to: Hirotoshi
Nakamura, Department of Internal Medicine II, Hamamatsu University
School of Medicine, Handayama 1-20-1, Hamamatsu, Shizuoka, Japan.
E-mail: [email protected].
Disclosure Statement: The authors have nothing to disclose.
References
1. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y,
Izumi M 1991 Differences and similarities in the diagnosis and treatment of
Graves’ disease in Europe, Japan, and the United States. Thyroid 1:129 –135
2. Shiroozu A, Okamura K, Ikenoue H, Sato K, Nakashima T, Yoshinari M,
3.
4.
5.
6.
9.
10.
11.
12.
13.
14.
15.
Fujishima M, Yoshizumi T 1986 Treatment of hyperthyroidism with a small
single daily dose of methimazole. J Clin Endocrinol Metab 63:125–128
Mashio Y, Beniko M, Ikota A, Mizumoto H, Kunita H 1988 Treatment of
hyperthyroidism with a small single daily dose of methimazole. Acta Endocrinol (Copenh) 119:139 –144
Mashio Y, Beniko M, Matsuda A, Koizumi S, Matsuya K, Mizumoto H, Ikota
A, Kunita H 1997 Treatment of hyperthyroidism with a small single daily dose
of methimazole: a prospective long-term follow-up study. Endocr J 44:553–558
Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari M, Fujishima M 1987
Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil
in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 65:719 –723
Nicholas WC, Fischer RG, Stevenson RA, Bass JD 1995 Single daily dose of
methimazole compared to every 8 hours propylthiouracil in the treatment of
hyperthyroidism. South Med J 88:973–976
Kallner G, Vitols S, Ljunggren JG 1996 Comparison of standardized initial
doses of two antithyroid drugs in the treatment of Graves’ disease. J Intern Med
239:525–529
Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W,
Vichayanrat A 2001 Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol (Oxf) 54:385–
390
He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS,
Kuo SW 2004 Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves’ hyperthyroidism. Clin Endocrinol (Oxf)
60:676 – 681
Gwinup G 1978 Prospective randomized comparison of propylthiouracil.
JAMA 239:2457–2459
Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, Reinwein D 1995
Response to methimazole in Graves’ disease. The European Multicenter Study
Group. Clin Endocrinol (Oxf) 43:257–263
Page SR, Sheard CE, Herbert M, Hopton M, Jeffcoate WJ 1996 A comparison
of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol (Oxf) 45:511–516
Werner MC, Romaldini JH, Bromberg N, Werner RS, Farah CS 1989 Adverse
effects related to thionamide drugs and their dose regimen. Am J Med Sci
297:216 –219
Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ 1993 Hepatic injury
during propylthiouracil therapy in patients with hyperthyroidism. A cohort
study. Ann Intern Med 118:424 – 428
Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA 1997 Fifty years of
experience with propylthiouracil-associated hepatotoxicity: what have we
learned? J Clin Endocrinol Metab 82:1727–1733
JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the
endocrine community.